Deeplex® Myc-TB: Pursue the global deployment of the innovative solution for predicting antibiotic resistance in tuberculosis
GenoScreen and ScienceVision announce an agreement to commercialize the Deeplex® Myc-TB test in Malaysia, Myanmar and Brunei.
Bureau Veritas Certification has renewed GenoScreen's ISO 9001:2015 and ISO 13485:2016 certifications for 3 years, demonstrating our continuous commitment to quality and efforts to satisfy our customers as best as possible, in compliance with legal and regulatory requirements.
Tuberculosis has been a major scourge since antiquity. The fight against this disease requires ever more efficient technologies. GenoScreen, a French biotech company, has recently developed a new weapon for predicting antibiotic resistance in the germs responsible for this disease. This new test, which comes in the form of a kit, quickly and efficiently detects the genetic mutations in the DNA of pathogenic germs and guides doctors in their medical prescriptions. This test is already being implemented in some thirty countries.
Adebiotech is organising a new day dedicated to innovative approaches in the fight against antibiotic resistance. The event will take place on September 16, 2021 at the Genopôle (Campus 1) in Evry-Courcouronnes - FRANCE.
Conferences will address preventive actions (microbiota, immunomodulation, new vaccines...), innovations in diagnostics (AI and Big data, metagenomics, new rapid diagnostics...), and some new therapeutic approaches (phagotherapy, antimicrobial peptides, bacteriocins...). The event will close with a round table/discussion on the marketing of new treatments, their financing and regulatory aspects.
During Session 2 - Innovative Diagnostics, which will take place from 11:30 am to 12:30 pm, Nelly BADALATO, Ph.D. R&D Project Manager at GenoScreen will talk about "Targeted Sequencing: a toolbox for antibiotic resistance monitoring and diagnosis".
The innovative Deeplex® Myc-TB test for antibiotic resistance prediction in tuberculosis, created by GenoScreen, has been evaluated by an Indian research team. By testing approximately 40 clinical samples, this study validates the use of Deeplex® Myc-TB, by demonstrating its usability in hospital environments. These results confirm the interest of its deployment in hospital routines for the benefit of patients' health.
Biodiversity, species preservation, ecosystem protection...
All are hot topics to which GenoScreen's genotyping solutions provide answers.
Press release - Researchers from GenoScreen and the Cardio-Thoracic Research Centre of Bordeaux (Inserm U1045) have demonstrated relationships between microorganisms in indoor air and those in asthmatic patients’ lungs. This work, published in the Journal of Allergy and Clinical Immunology and highlighted by the American Academy of Allergy, Asthma and Immunology (AAAI), also shows a variation in these micro- and mycobiota according to the patients’ inflammatory reaction type (T2 endotype).